Haiyan Tang is of counsel in the Litigation practice of Paul Hastings and splits her time between Chicago and Shanghai offices. Ms. Tang’s practice focuses on government enforcement, investigations, and litigations.

Ms. Tang has advised numerous companies on sensitive enforcement matters involving the U.S. Foreign Corrupt Practice Act (“FCPA”) and other corruption enforcement regimes. In addition, she acted as a leading global pharmaceutical company’s Acting Compliance Regional Director in China during a period in which the company was under a DOJ/SEC self-reporting obligation. She previously practiced as a litigator in a top international law firm in California for four years and litigation associate in other two international law firms in China for three years. Ms. Tang is admitted in California only.

Recent Representations

Monitorships and Self-Reporting

- Advised multiple U.S. companies doing business in China with regard to oversight by a compliance monitor, including implementation of compliance policies and procedures, testing, evaluation of compliance issues, and responses to monitor requests.
- Advised multiple U.S. companies with regard to self-reporting obligations arising from FCPA settlements with the Department of Justice/S.E.C., including concerning internal investigations, remediation, and reporting to the government.

FCPA Compliance and Policies

- Advised a variety of entities with regard to devising and organizing anti-corruption compliance programs and training programs; drafting compliance policies and procedures; and implementing monitoring and testing structures.

Compliance Investigations

- Acted as a leading global pharmaceutical company’s Compliance Regional
Director in China, managing the Company’s China investigations, participating in proactive compliance reviews, working with multiple stakeholders to remediate issues identified in investigations, and developing compliance strategies.

- Advised numerous companies in connection with FCPA related internal investigations and government enforcement actions involving the U.S. Department of Justice, the SEC, and multiple foreign enforcement agencies.
- Lead an internal investigation into potential bribery and embezzlement issues regarding a U.S. company’s operations in China.
- Conducted an internal investigation into allegations of bid rigging and self-dealing regarding a few senior managers of a U.S. company’s operations in China.
- Conducted internal investigations in connection with Chinese government’s investigation of potential bribery issues of a few U.S. companies.
- Conducted an internal investigation of possible FCPA violations in China for a U.S. listed medical devices company.
- Conducted an internal investigation of possible FCPA violations in Macau for a U.S. listed resort company.

**Intellectual Property Litigations**

- Advised a U.S. company in a trade secret misappropriation incident in China, when the ex-employees of the U.S. company took critical technical data and started a competing company in the same industry.
- Managed a trademark infringement lawsuit in China for a top U.S. fashion company.
- Represented a prominent Chinese online travel company in domain disputes before the World Intellectual Property Organization Arbitration and Mediation Center; and managing the company’s global trademark applications.
- Defended a multinational photography and imaging company headquartered in Tokyo, Japan in a patent infringement lawsuit regarding Green Fluorescence Protein optical imaging technology in the Central District of California.
- Represented a leading biotechnology company in a U.S. state court trade secret case regarding RNAi delivery system.
- Represented a leading Japanese food and chemical company before the ITC concerning animal feed production technology.
- Represented a leading semiconductor company in Silicon Valley and a major semiconductor company in Taiwan in two patent infringement cases regarding off-line conversion integrated circuits in the District of Delaware and the Northern District of California.
- Represented a leading computer manufacturing company before the ITC concerning semiconductor packaging technology and in its 300 million dollar
acquisition of a Silicon Valley startup company.

- Represented a major Taiwanese company that conducts research and development, design, manufacturing and sales of DRAM products in a patent infringement case regarding certain standardized DRAM technology.
- Represented a major U.S. software company in many trademark cases in various jurisdictions.
- Advised a leading Chinese internet search company on internet advertising issues.

**Speaking Engagements and Publications**

Ms. Tang is a co-author of the following publications:

- General Exclusion Orders and Their Impact on Products, Companies, and Global Markets, U.S. Section 337 Investigation Case Analysis, to be published by the Ministry of Commerce of the P.R.C.
- Implications of the Sucralose ITC Investigation For Chinese Companies, Managing Intellectual Property, 2009
- The Mammalian Golgi Regulates Numb Signaling in Asymmetric Cell Division by Releasing ACBD3 during Mitosis, Cell, 2007
- The Enigma of the Numb-Notch Relationship during Mammalian Embryogenesis, Developmental Neuroscience, 2006
- Numb Proteins Specify Asymmetric Cell Fates Via an Endocytosis and Proteasome Independent Pathway, Molecular Cellular Biology, 2005

**Education**

- The George Washington University Law School, J.D., 2007
- Yale University, Ph.D, Neuroscience, 2004
- Yale University, M. Phil, Neuroscience, 2002
- Nanjing University, B.Sc., Biology, 1996

**Insights**

**August 28, 2014**

Legislative Reform of China’s Healthcare Sector Targets Corruption: Implications for Multinational Companies